INNOVATE Corp. Announces Second Quarter 2026 Results

INNOVATE Corp. Announces Second Quarter 2026 Results INNOVATE Corp. Announces Second Quarter 2026 Results GlobeNewswire August 06, 2026


- Infrastructure: DBM Global delivered record results in the second quarter with year-over-year revenue growth of ~78%
- Life Sciences: MediBeacon continued targeted introduction of TGFR system at centers of excellence in the U.S. and China
- Spectrum: Successful closing of Broadcasting refinancing and INNOVATE agreed to partial sale of Broadcasting

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- INNOVATE CORP.® (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the second quarter.

Financial Summary

(in millions, except per share amounts)Three Months Ended June 30, Six Months Ended June 30,
 2026
 2025 Increase / (Decrease) 2026 2025 Increase / (Decrease)
Revenue$421.6  $242.0  74.2% $786.4  $516.2  52.3%
Net income (loss) attributable to common stockholders and participating preferred stockholders$10.4  $(22.0) 147.3% $(6.8) $(46.8) 85.5%
Basic earnings (loss) per share attributable to common stockholders$0.74  $(1.67) 144.3% $(0.51) $(3.56) 85.7%
Diluted earnings (loss) per share attributable to common stockholders$0.71  $(1.67) 142.5% $(0.51) $(3.56) 85.7%
Total Adjusted EBITDA(1)$46.3  $15.7  194.9% $66.0  $22.9  188.2%

(1) Reconciliation of GAAP to Non-GAAP measures follows.

Commentary

"INNOVATE delivered a strong second quarter and continued to execute on several important strategic priorities across the portfolio," said Avie Glazer, Chairman of INNOVATE. “At Infrastructure, DBM Global delivered a record-breaking quarter, reflecting continued strong financial performance with margin expansion and backlog growth. During the quarter, Broadcasting strengthened its financial position through a refinancing transaction, and our Life Sciences businesses continued to advance key commercialization and regulatory initiatives."

"We continue to make progress across our key strategic priorities and believe the momentum we saw during the second quarter reinforces the value and potential of our portfolio," said Paul Voigt, Interim CEO of INNOVATE. “DBM Global delivered exceptional results, supported by strong execution, robust backlog growth, and favorable end-market demand. At MediBeacon, we continue to focus on commercialization efforts, reimbursement initiatives, and global regulatory activities, while R2 exited the quarter with strong demand and an expanding international presence. We remain focused on strengthening our balance sheet, advancing growth initiatives and creating long-term value for our shareholders."

Second Quarter 2026 and Recent Highlights

Infrastructure

Life Sciences

Spectrum

Second Quarter 2026 Financial Highlights

          
REVENUE by OPERATING SEGMENT         
                
(in millions)Three Months Ended June 30, Six Months Ended June 30,
 2026
 2025
 Increase /
(Decrease)
 2026
 2025
 Increase/
(Decrease)
Infrastructure$414.0  $233.1  $180.9  $771.9  $498.0  $273.9 
Life Sciences 2.2   3.2   (1.0)  3.8   6.3   (2.5)
Spectrum 5.4   5.7   (0.3)  10.7   11.9   (1.2)
Consolidated INNOVATE$421.6  $242.0  $179.6  $786.4  $516.2  $270.2 
                        
 
NET INCOME (LOSS) by OPERATING SEGMENT
            
(in millions)Three Months Ended June 30, Six Months Ended June 30,
 2026 2025 Increase /
(Decrease)
 2026 2025 Increase /
(Decrease)
Infrastructure$26.4  $5.5  $20.9  $35.7  $10.1  $25.6 
Life Sciences (2.3)  (6.5)  4.2   (5.6)  (14.1)  8.5 
Spectrum 8.4   (6.1)  14.5   1.9   (11.5)  13.4 
Non-Operating Corporate (21.8)  (12.7)  (9.1)  (38.1)  (28.8)  (9.3)
Other and eliminations                 
Net income (loss) attributable to INNOVATE Corp.$10.7  $(19.8)  30.5  $(6.1) $(44.3) $38.2 
Less: Preferred stock dividends 0.3   2.2   (1.9)  0.7   2.5   (1.8)
Net income (loss) attributable to common stockholders and participating preferred stockholders$10.4  $(22.0) $32.4  $(6.8) $(46.8) $40.0 
                        
        
ADJUSTED EBITDA by OPERATING SEGMENT       
            
(in millions)Three Months Ended June 30, Six Months Ended June 30,
 2026 2025 Increase /
(Decrease)
 2026 2025 Increase/
(Decrease)
Infrastructure$48.7  $19.3  $29.4  $71.7  $36.0  $35.7 
Life Sciences (0.8)  (2.6)  1.8   (2.8)  (11.3)  8.5 
Spectrum 0.4   1.0   (0.6)  1.1   2.4   (1.3)
Non-Operating Corporate (2.0)  (2.0)     (4.0)  (4.2)  0.2 
Other and eliminations                 
Total Adjusted EBITDA(1)$46.3  $15.7  $30.6  $66.0  $22.9  $43.1 

(1) Reconciliation of GAAP to Non-GAAP measures follows.

Conference Call

INNOVATE will host a live conference call to discuss its second quarter 2026 financial results and operations today at 4:30 p.m. ET. The Company will post an earnings supplemental presentation in the Investor Relations section of the INNOVATE website at innovate-ir.com to accompany the conference call. Dial-in instructions for the conference call and the replay follows.

*Available approximately three hours after the end of the conference call through August 20, 2026.

About INNOVATE

INNOVATE is a portfolio of best-in-class assets in three key areas of the new economy – Infrastructure, Life Sciences and Spectrum. Dedicated to stakeholder capitalism, INNOVATE employs approximately 3,700 people across its subsidiaries. For more information, please visit: www.INNOVATECorp.com.

Contacts

Investor Contact:
Anthony Rozmus
ir@innovatecorp.com
(212) 235-2691

Non-GAAP Financial Measures

In this press release, INNOVATE refers to certain financial measures that are not presented in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), including Total Adjusted EBITDA (excluding discontinued operations, if applicable) and Adjusted EBITDA for its operating segments. In addition, other companies may define Adjusted EBITDA differently than we do, which could limit its usefulness.

Adjusted EBITDA

Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization’s operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company’s ability to service debt. While management believes that non-U.S. GAAP measurements are useful supplemental information, such adjusted results are not intended to replace our U.S. GAAP financial results. Using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other U.S. GAAP financial measures, as this non-U.S. GAAP measure excludes certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and does not purport to be an alternative to net income (loss) or other U.S. GAAP financial measures as a measure of our operating performance.

The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) attributable to INNOVATE Corp., excluding: discontinued operations, if applicable; depreciation and amortization; other operating (income) loss (which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, (gains) losses on lease modifications, and asset impairment expense); interest expense; (gain) loss on extinguishment of debt; other (income) expense, net; income tax expense (benefit); non-controlling interests; share-based compensation expense; realignment and exit costs; facility commissioning costs; debt refinancing costs and acquisition and disposition costs.

Cautionary Statement Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains, and certain oral statements made by our representatives from time to time may contain, “forward-looking statements.” Generally, forward-looking statements include information describing actions, events, results, strategies and expectations and are generally identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions. Such forward-looking statements are based on current expectations and inherently involve certain risks, assumptions and uncertainties. The forward-looking statements in this press release include, without limitation, any statements regarding INNOVATE’s plans and expectations for future growth and ability to capitalize on potential opportunities, the achievement of INNOVATE’s strategic objectives, expectations for performance of new projects and realization of revenue from the backlog at DBMG and the Infrastructure segment, anticipated success from the continued sale of new products in the Life Sciences segment, expectations for advertising revenue growth, new technologies, networks and stations, and potential commercial opportunities in datacasting in the Spectrum segment. Such statements are based on the beliefs and assumptions of INNOVATE’s management and the management of INNOVATE’s subsidiaries and portfolio companies.

The Company believes these judgments are reasonable, but these statements are not guarantees of performance, results or the creation of stockholder value and the Company’s actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of important factors, both positive and negative, including those that may be identified in subsequent statements and reports filed with the Securities and Exchange Commission (“SEC”), including in our reports on Forms 10-K, 10-Q, and 8-K. Such important factors include, without limitation: our dependence on distributions from our subsidiaries to fund our operations and payments on our obligations; substantial doubt about our ability to continue operating as a going concern; our expectations and timing with respect to any strategic dispositions and sales of our operating subsidiaries, or businesses, including, without limitation, the sales of DBMG and Broadcasting; obtaining FCC regulatory approval for the Broadcasting merger; the possibility of indemnification claims arising out of divestitures of businesses; the impact on our business and financial condition of our substantial indebtedness and any significant additional indebtedness and other financing obligations we may incur; our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all; our anticipated business profile following the highly substantial asset dispositions we are pursuing, including the potential absence of material operating revenue and uncertainty regarding the nature of any future operations; our dependence on the retaining and recruitment of key personnel; volatility in the trading price of our common stock; the impact of potential supply chain disruptions, labor shortages and increases in overall price levels, including in steel and transportation costs; interest rate environment; developments relating to the hostilities in Ukraine, the Middle East and Venezuela; increased competition in the markets in which our operating segments conduct their businesses; our ability to successfully identify any strategic acquisitions or business opportunities; uncertain global economic conditions in the markets in which our operating segments conduct their businesses; changes in regulations and tax laws; covenant noncompliance risk; tax consequences associated with our acquisitions, holding and disposition of target companies and assets; the ability of our operating segments to attract and retain customers; and our expectations regarding the timing, extent and effectiveness of any cost reduction initiatives and management’s ability to moderate or control discretionary spending.

Although INNOVATE believes its expectations and assumptions regarding its future operating performance are reasonable, there can be no assurance that the expectations reflected herein will be achieved. These risks and other important factors discussed under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.

You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to INNOVATE or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and unless legally required, INNOVATE undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    
INNOVATE CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in millions, except shares and per share amounts)
    
 Three Months Ended June 30, Six Months Ended June 30,
 2026 2025 2026 2025
Revenue$421.6  $242.0  $786.4  $516.2 
Cost of revenue 342.1   196.4   653.4   425.1 
Gross profit 79.5   45.6   133.0   91.1 
Operating expenses:       
Selling, general and administrative 41.5   35.1   80.9   72.9 
Depreciation and amortization 3.5   4.4   7.7   8.8 
Other operating loss (income)    1.2   (0.1)  1.1 
Income from operations 34.5   4.9   44.5   8.3 
Other (expense) income:       
Interest expense (27.6)  (21.4)  (52.1)  (41.6)
Gain (loss) on extinguishment of debt 18.4   (0.3)  18.4   (0.3)
Loss from equity investees          (5.9)
Other income, net 0.2      0.5   4.0 
Income (loss) from operations before income taxes 25.5   (16.8)  11.3   (35.5)
Income tax expense (13.1)  (4.2)  (16.0)  (11.3)
Net income (loss) 12.4   (21.0)  (4.7)  (46.8)
Net (income) loss attributable to non-controlling interests and redeemable non-controlling interests (1.7)  1.2   (1.4)  2.5 
Net income (loss) attributable to INNOVATE Corp. 10.7   (19.8)  (6.1)  (44.3)
Less: Preferred stock dividends 0.3   2.2   0.7   2.5 
Net income (loss) attributable to common stockholders and participating preferred stockholders$10.4  $(22.0) $(6.8) $(46.8)
        
Earnings (loss) per common share       
Basic$0.74  $(1.67) $(0.51) $(3.56)
Diluted$0.71  $(1.67) $(0.51) $(3.56)
        
Weighted-average common shares outstanding       
Basic 13,374,803   13,146,750   13,360,333   13,130,930 
Diluted 13,968,004   13,146,750   13,360,333   13,130,930 
                


INNOVATE CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in millions, except share amounts)
    
 June 30,
2026
 December 31,
2025
Assets   
Current assets   
Cash and cash equivalents$87.8  $108.2 
Accounts receivable, net 284.4   239.4 
Contract assets 52.6   64.1 
Inventory 14.8   16.0 
Current assets held for sale 5.5   6.8 
Other current assets 34.2   16.9 
Total current assets 479.3   451.4 
Investments 2.2   1.8 
Deferred tax asset 2.0   2.0 
Property, plant and equipment, net 136.3   131.6 
Goodwill 105.7   105.6 
Intangibles, net 44.0   47.3 
Assets held for sale 169.5   167.7 
Other assets 67.7   42.7 
Total assets$1,006.7  $950.1 
Liabilities, temporary equity and stockholders’ deficit   
Current liabilities   
Accounts payable$137.2  $140.5 
Accrued liabilities 77.9   64.8 
Current portion of debt obligations 553.9   518.6 
Contract liabilities 182.7   171.9 
Current liabilities held for sale 118.7   126.5 
Other current liabilities 13.0   11.8 
Total current liabilities 1,083.4   1,034.1 
Deferred tax liability 1.9   2.1 
Debt obligations 62.1   80.3 
Liabilities held for sale 22.1   19.4 
Other liabilities 57.2   29.5 
Total liabilities 1,226.7   1,165.4 
Commitments and contingencies   
Temporary equity   
Preferred Stock Series A-3 and Preferred Stock Series A-4, $0.001 par value 9.7   9.3 
Shares authorized: 20,000,000; Shares issued and outstanding: 6,125 of Series A-3; 1,937 of Series A-4   
Redeemable non-controlling interests (1.1)  1.6 
Total temporary equity 8.6   10.9 
Stockholders’ deficit   
Common stock, $0.001 par value     
Shares authorized: 250,000,000; Shares issued: 13,818,904; Shares outstanding: 13,641,866 and 13,655,062, respectively   
Additional paid-in capital 352.9   350.1 
Treasury stock, at cost: 177,038 and 163,842 shares, respectively (5.6)  (5.6)
Accumulated deficit (588.6)  (582.5)
Accumulated other comprehensive loss (1.9)  (2.1)
Total INNOVATE Corp. stockholders’ deficit (243.2)  (240.1)
Non-controlling interests 14.6   13.9 
Total stockholders’ deficit (228.6)  (226.2)
Total liabilities, temporary equity and stockholders’ deficit$1,006.7  $950.1 
        


INNOVATE CORP.
RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA
(Unaudited, in millions)
  
 Three Months Ended June 30, 2026
 Infrastructure Life Sciences Spectrum Non-Operating Corporate Other and Eliminations  INNOVATE
Net income (loss) attributable to INNOVATE Corp.$26.4  $(2.3) $8.4  $(21.8) $  $10.7 
Adjustments to reconcile net income (loss) to Adjusted EBITDA:            
Depreciation and amortization 2.8      0.7         3.5 
Depreciation and amortization (included in cost of revenue) 3.5               3.5 
Interest expense 1.4   2.1   6.8   17.3      27.6 
Gain on extinguishment of debt       (18.4)        (18.4)
Other (income) expense, net (1.8)     1.9   (0.3)     (0.2)
Income tax expense 11.1         2.0      13.1 
Non-controlling interests 2.5   (0.6)  (0.2)        1.7 
Share-based compensation expense          0.4      0.4 
Realignment and exit costs 0.2               0.2 
Facility commissioning costs 2.4               2.4 
Debt refinancing costs          0.2      0.2 
Acquisition and disposition costs 0.2      1.2   0.2      1.6 
Adjusted EBITDA$48.7  $(0.8) $0.4  $(2.0) $  $46.3 
                        


 Three Months Ended June 30, 2025
 Infrastructure Life Sciences Spectrum Non-Operating Corporate Other and Eliminations INNOVATE
Net income (loss) attributable to INNOVATE Corp.$5.5  $(6.5) $(6.1) $(12.7) $  $(19.8)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:            
Depreciation and amortization 3.1   0.1   1.2         4.4 
Depreciation and amortization (included in cost of revenue) 3.0               3.0 
Other operating loss 1.2               1.2 
Interest expense 2.4   5.2   3.9   9.9      21.4 
Loss on extinguishment of debt 0.3               0.3 
Other (income) expense, net (0.3)     2.3   (2.0)      
Income tax expense 2.1         2.1      4.2 
Non-controlling interests 0.6   (1.4)  (0.4)        (1.2)
Share-based compensation expense          0.7      0.7 
Realignment and exit costs 1.4      0.1         1.5 
Adjusted EBITDA$19.3  $(2.6) $1.0  $(2.0) $  $15.7 
                        


INNOVATE CORP.
RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA
(Unaudited, in millions)
  
 Six Months Ended June 30, 2026
 Infrastructure Life Sciences Spectrum Non-Operating Corporate Other and Eliminations INNOVATE
Net income (loss) attributable to INNOVATE Corp.$35.7  $(5.6) $1.9  $(38.1) $  $(6.1)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:            
Depreciation and amortization 5.7   0.1   1.9         7.7 
Depreciation and amortization (included in cost of revenue) 6.7               6.7 
Other operating income       (0.1)        (0.1)
Interest expense 3.2   4.0   10.8   34.1      52.1 
Gain on extinguishment of debt       (18.4)        (18.4)
Other (income) expense, net (1.9)     4.4   (3.0)     (0.5)
Income tax expense 15.2         0.8      16.0 
Non-controlling interests 3.4   (1.4)  (0.6)        1.4 
Share-based compensation expense    0.1      0.9      1.0 
Realignment and exit costs 0.5               0.5 
Facility commissioning costs 3.0               3.0 
Debt refinancing costs          0.2      0.2 
Acquisition and disposition costs 0.2      1.2   1.1      2.5 
Adjusted EBITDA$71.7  $(2.8) $1.1  $(4.0) $  $66.0 
                        


 Six Months Ended June 30, 2025
 Infrastructure Life Sciences Spectrum Non-Operating Corporate Other and Eliminations INNOVATE
Net income (loss) attributable to INNOVATE Corp.$10.1  $(14.1) $(11.5) $(28.8) $  $(44.3)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:            
Depreciation and amortization 6.2   0.2   2.4         8.8 
Depreciation and amortization (included in cost of revenue) 6.5               6.5 
Other operating loss 1.1               1.1 
Interest expense 4.5   9.7   7.6   19.8      41.6 
Loss on extinguishment of debt 0.3               0.3 
Other (income) expense, net (0.6)  (4.5)  4.5   (3.4)     (4.0)
Income tax expense 4.4         6.9      11.3 
Non-controlling interests 1.0   (2.8)  (0.7)        (2.5)
Share-based compensation expense    0.2      1.3      1.5 
Realignment and exit costs 2.5      0.1         2.6 
Adjusted EBITDA$36.0  $(11.3) $2.4  $(4.2) $  $22.9 
                        

Primary Logo